GSA Capital Partners LLP cut its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 62.9% in the ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

We recently compiled a list of the 10 Worst-Performing Growth Stocks in 2024. In this article, we are going to take a look at ...

On Monday, ACADIA Pharmaceuticals Inc (ACAD) stock saw a decline, ending the day at $14.62 which represents a decrease of $-0.19 or -1.28% from the prior close of $14.81. The stock opened at $14.73 ...

The stock currently trades at just under $18.00 a share and sports an approximate market capitalization of $2.95 billion.

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

View ACADIA Pharmaceuticals Inc. (ACAD) current and estimated P/E ratio data provided by Seeking Alpha.